EBS Emergent BioSolutions Inc.

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024

GAITHERSBURG, Md., May 10, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2024 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 23, 2024 at 9:00 am eastern time.

HOW TO PARTICIPATE IN THE VIRTUAL ANNUAL MEETING

As described in the , stockholders of record are eligible to participate in and ask questions during the Virtual Annual Meeting.

Visit this and enter the 16-digit Control Number provided on the proxy card, voting instruction form or notice received from the Company to log into the webcast. Only one stockholder per 16-digit Control Number can access the Virtual Annual Meeting.

Beneficial owners of shares held in street name will need to follow the instructions provided by the broker, bank or other nominee that holds their shares.

Those without a Control Number may attend as guests in listen-only mode and will not have the option to vote their shares or ask questions during the Virtual Annual Meeting.

ALL PARTICIPANTS ARE ENCOURAGED TO LOG IN AND ACCESS THE WEBCAST 15 MINUTES BEFORE THE VIRTUAL ANNUAL MEETING BEGINS.

Further instructions on how to attend, participate in and vote at the Virtual Annual Meeting, including how to demonstrate your ownership of the Company’s common stock as of the record date, are available .

A replay of the audio webcast will be made available on the .

About Emergent BioSolutions 

At Emergent, our mission is to protect and enhance life. For 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our and follow us on , , , and .

Investor Contact:

Richard S. Lindahl

Executive Vice President, CFO

Media Contact:

Assal Hellmer

Vice President, Communications



EN
10/05/2024

Underlying

EBSEmergent BioSolutions Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

EUR 229.75
EBS Emergent BioSol...

Emergent BioSolutions Inc.: Update following rating affirmation and ou...

Our credit view of this issuer reflects its niche expertise and competencies in products treating public health threats, constrained by its negative earnings in CDMO business.

EBS EMERGENT BIOSOLUTIONS INC.
05/10/24 May 10, 2024 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders o...

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024 GAITHERSBURG, Md., May 10, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2024 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 23, 2024 at 9:00 am eastern time. HOW TO PARTICIPATE IN THE VIRTUAL ANNUAL MEETINGAs described in the , stockholders of record are eligible to participate in and ask questions during the Virtual Annual Meeting. Visit this and enter the 16-digit Control Number provide...

May 10, 2024 1 EN
EUR 165.42
EBS Emergent BioSol...

Moody's Ratings affirms Emergent BioSolutions' Caa1 CFR; revises outlo...

Moody's Ratings (Moody's) affirmed the ratings of Emergent BioSolutions Inc. ("Emergent") including the Caa1 Corporate Family Rating (CFR), the Caa1-PD Probability of Default Rating (PDR) and the Caa3 senior unsecured rating. The Speculative Grade Liquidity Rating (SGL) remains unchanged at SGL-4. A...

EBS EMERGENT BIOSOLUTIONS INC.
05/09/24 May 9, 2024 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Reports First Quarter 2024 Financial Results

Emergent BioSolutions Reports First Quarter 2024 Financial Results First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance rangeFirst Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of $66.9 millionUpdates FY 2024 guidance GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2024. "We delivered a strong quarter with growth across all our key products,” said Joe Papa, President and CEO at Emergent. “We also took significant act...

May 1, 2024 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Announces Strategic Operational Changes to Stabi...

Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position Proactive changes aim to ensure long-term sustainability and growth, optimize operations, streamline processes, and allocate resources more efficientlyReorganization will align with evolving business goals, strategic priorities and new operational planOverall efforts expected to deliver annual cost savings of approximately $80 million  GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced the next phase of its new operational plan that consolidates...

May 1, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch